Ironwood price target raised to $10.50 from $9 at TD Cowen

TD Cowen analyst Boris Peaker raised the firm’s price target on Ironwood to $10.50 from $9 and keeps a Market Perform rating on the shares. The firm ahead of its Phase 3 apraglutide data from the STARS trial. Cowen anticipates that apraglutide will show efficacy similar to other GLP-2 analogues, which will likely lead to approval and launch in 2025.